Valeant Keeps full year earnings guidance unchanged

Discussion in 'Valeant Pharmaceuticals' started by RobertPhillips900, Nov 7, 2017 at 9:49 AM.

  1. RobertPhillips900

    Joined:
    Aug 29, 2016
    Messages:
    51
    Likes Received:
    0
    Valeant posted a quarterly profit helped by the strong performance of its Bausch and Lomb Business.
    Net income attributable to Valeant rose to $1.30Bil, or $3.69 per share, during the quarter , compared with a loss of $1.22Bil, or $3.49 per share, a year earlier.

    Total revenue fell 10.5% to $2.22Bil, reflecting volume declines in its US diversified products and branded businesses.

    Take a look at the earnings highlights including the guidance http://alph.st/b07a566e
     

  2. anonymous

    anonymous Guest

    Nice try. Still a garbage company that no one wants to work for.